C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home Markets Loading…
CLVR Equity

Clever Leaves Holdings

NASDAQ · CLVR

$0.00
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 3/5
38/100 composite
Fundamentals31
Regulatory50
Market40
Editorial30
Composite · trailing 12 months

Clever Leaves Holdings earns a Neutral rating with 3/5 conviction, reflecting a 37.9 composite that lacks the breadth required for a directional stance. Regulatory is the strongest pillar at 50, supported by a favorable LATAM jurisdiction score and no enforcement hits. Market contributes 40, although the absence of an available quote limits confirmation from institutional pricing feeds. Fundamentals score 31 as modest growth and a respectable gross margin are overwhelmed by deeply negative operating profitability, ongoing losses, and stretched financial condition. Editorial contributes 30, consistent with no recent newsroom or brief activity in CIN newsroom coverage. The resulting profile sits firmly in the Neutral band: regulatory standing provides support, while weak economics, limited filing cadence, and minimal information flow cap conviction.

Licensed fundamentals data show year-over-year revenue growth of roughly 5.4%, offering evidence of expansion but not enough acceleration to offset the cost structure. Gross margin approaches 37.6%, a constructive feature within the fundamentals pillar, yet operating margin stands near negative 106%, demonstrating substantial operating deleverage. Net income remains a loss of approximately $17.9 million, while EBITDA is negative by about $13.2 million. Those figures reinforce the stretched classification and the low cash-runway subscore rather than indicating financial stabilization. Primary regulatory filings show no recorded filing date, while the regulatory dataset contains no events over either the latest 90-day or 180-day periods. The absence of enforcement hits strengthens the regulatory score, but the weak cadence subscore restricts the pillar from translating into a higher composite.

The clearest forward catalyst resides in the regulatory pillar, where the LATAM jurisdiction posture and clean enforcement record already establish the strongest foundation in the scorecard. A renewed filing sequence could improve transparency, validate operating continuity, and lift the cadence component without relying on market momentum or editorial attention. That development would also provide fresher evidence against which revenue growth, margin performance, and the stretched financial condition can be assessed. The single most important signal to watch is a new primary regulatory filing that reestablishes consistent reporting cadence.

Scored: 2026-09-22Valid through: 2026-11-06Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Phone
+1-201-565-3345
SEC CIK
0001819615
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$0.0M
Enterprise value
$-4.7M
EV / EBITDA
-0.07
Revenue (TTM)
$17.4M
Gross profit (TTM)
$6.6M
EBITDA
$-13.2M
Operating margin
-105.9%
Profit margin
-102.8%
Rev growth YoY
5.4%
Return on equity
-61.3%
Return on assets
-23.4%
EPS (TTM)
$-2.11
Wall St. target price
$24.00
Shares outstanding
1.8M
Beta
1735.91
Full-time employees
296
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for Clever Leaves Holdings (CLVR)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Clever Leaves Holdings (CLVR), a cannabis-sector equity listed on NASDAQ. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown, micro-cap. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for CLVR are maintained by Cannabis Investor News and refreshed throughout the trading day.